Urologix (Urologix) Debt-to-Asset : 1.06 (As of Mar. 2015)

View and export this data going back to 1996. Start your Free Trial

What is Urologix Debt-to-Asset?

Urologix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2015 was $1.80 Mil. Urologix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2015 was $3.54 Mil. Urologix's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2015 was $5.02 Mil. Urologix's debt to asset for the quarter that ended in Mar. 2015 was 1.06.

Urologix Debt-to-Asset Historical Data

The historical data trend for Urologix's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix Debt-to-Asset Chart

Urologix Annual Data

Trend

Jun05

Jun06

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Debt-to-Asset

Get a 7-Day Free Trial

0.43

0.94

Urologix Quarterly Data
	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
Debt-to-Asset	Get a 7-Day Free Trial															0.57	0.94	0.97	1.00	1.06

Competitive Comparison of Urologix's Debt-to-Asset

For the Medical Devices subindustry, Urologix's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Urologix's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Urologix's Debt-to-Asset falls into.

Urologix Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Urologix's Debt-to-Asset for the fiscal year that ended in Jun. 2014 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.747	+	4.586)	/	5.667
	=	0.94

Urologix's Debt-to-Asset for the quarter that ended in Mar. 2015 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.795	+	3.537)	/	5.023
	=	1.06

Urologix (OTCPK:ULGX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Urologix Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Urologix's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Urologix (Urologix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447

Website

http://www.urologix.com

Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.

Executives

Emery Sidney W Jr	director	C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler	director	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet	director, officer: CEO	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore	director
Guy C Jackson	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks	director	ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon	officer: Chief Technology Officer
Bobby Ivan Griffin	director	1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo	officer: VP, Product Dev. & Operations	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote	director	649 SUMMIT AVENUE, ST PAUL MN 55105